- Details
- Alicia Morgans engages with Silke Gillessen to discuss the upcoming APCCC conference in 2024. The conference seeks to address some of the major questions in clinical practice such as the management of biochemical relapse after radical prostatectomy and the application of novel endocrine agents plus PARP inhibitors in first line mCRPC treatments. Side effects and their management, especially those...
|
- Details
- Neal Shore and Jason Efstathiou join Alicia Morgans at APCCC 2022 to discuss the current landscape in PSMA PET imaging. Drs Shore and Efstathiou share their thoughts on the agents they are using and the impacts of these new developments in imaging on staging and prognostication. Biographies: Jason Efstathiou, MD, Radiation Oncologist Professor of Radiation Oncology, Harvard Medical School, Vice-Ch...
|
- Details
- Alicia Morgans speaks with Neal Shore about advancements in treating metastatic castration-resistant prostate cancer (mCRPC). They discuss the implications of the newly approved PSMA-RLT lutetium-617, a radiopharmaceutical, adding it to a list of existing therapies such as taxane therapy, PARP inhibitors, and immunotherapies like sipuleucel-T. Dr. Shore emphasizes that monotherapy is no longer acc...
|
- Details
- Neal Shore joins Alicia Morgans during APCCC 2022 to discuss sequencing strategies to implement lutetium-617 for patients with metastatic castration-resistant prostate cancer (mCRPC). Drs. Shore and Morgans consider the many treatment options now available as Dr. Shore emphasizes that monotherapy should no longer be an option. Finally, important concerns about bone health and its impact on treatme...
|
- Details
- Evan Yu discusses the changing landscape of metastatic hormone-sensitive prostate cancer treatment with Alicia Morgans. Dr. Yu provides an overview of the many important questions and concerns clinicians must address in sequencing treatment for mCRPC patients in light of novel hormone therapy agents and the opportunity for triplet therapy. Biographies: Evan Yu, MD , Professor, Department of Medici...
|
- Details
- Alicia Morgans and Matthew Smith join Charles Ryan to discuss cancer survivorship. Drs Morgans and Smith explain the holistic role that a cancer survivorship program plays in the health and well-being of prostate cancer patients, including bone health, mental health, monitoring cardiovascular risk, and more. Biographies: Matthew R. Smith, MD, Ph.D., Professor of Medicine, Harvard Medical School, A...
|
- Details
- Emmanuel Antonarakis joins Alicia Morgans to discuss the immune checkpoint B7-H3 and its implications for prostate cancer treatment. Dr. Antonarakis provides an overview of clinical trials that tested B7-H3 and the encouraging findings of those trials. He also details some of the toxicities noted during the trials and plans for future studies given the measurable disease responses and PSA response...
|
- Details
- Joe O’Sullivan joins Alicia Morgans in a conversation about metastatic castration-resistant prostate cancer and the recent approval of lutetium-PSMA-617. As a radiation oncologist, Dr. O’Sullivan shares his views on effective sequencing of radium-223 and lutetium-177 for patients, especially given previous lines of treatment. Biographies: Joe M. O'Sullivan, MD, FRCPI, FFRRSCI, FRCR, Professor of R...
|
- Details
- Joaquin Mateo delivers a comprehensive talk on the challenges and opportunities of using genomic and clinical markers in non-metastatic castration-resistant prostate cancer (CRPC). Dr. Mateo emphasizes that while prognostic biomarkers can inform the likely course of the disease, there's currently no data to suggest that molecular profiling can improve patient outcomes in non-metastatic CRPC. He ar...
|
- Details
- Joe O'Sullivan introduces Stefano Fanti, the President of the EANM Congress, who delivers an insightful talk on the interpretation and confirmation of lesions positive on PSMA PET, with no correlation on CT. Dr. Fanti emphasizes the importance of guidelines, procedure adherence, and awareness of limitations in interpretation. He further explores how to confirm findings through correlative imaging,...
|
